Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care.

Thomas M, Radwan A, Stonham C, Marshall S.

COPD. 2014 Jun;11(3):300-9. doi: 10.3109/15412555.2013.841671. Epub 2013 Oct 23.

PMID:
24152210
2.

Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study.

Wurst KE, Shukla A, Muellerova H, Davis KJ.

COPD. 2014 Sep;11(5):521-30. doi: 10.3109/15412555.2014.922064. Epub 2014 Jun 19.

PMID:
24945236
3.

Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.

Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, Rossi A, Hutton C, Ashton VL, Stewart R, Bichel K.

Int J Chron Obstruct Pulmon Dis. 2014 Aug 27;9:889-904. doi: 10.2147/COPD.S62750. eCollection 2014.

4.

Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.

Asche CV, Leader S, Plauschinat C, Raparla S, Yan M, Ye X, Young D.

Int J Chron Obstruct Pulmon Dis. 2012;7:201-9. doi: 10.2147/COPD.S25805. Epub 2012 Mar 15.

5.

Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma.

Kew KM, Dahri K.

Cochrane Database Syst Rev. 2016 Jan 21;(1):CD011721. doi: 10.1002/14651858.CD011721.pub2. Review.

PMID:
26798035
6.

Comparative Effectiveness of Long-Acting Beta2 -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease.

Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA.

Pharmacotherapy. 2017 Apr;37(4):447-455. doi: 10.1002/phar.1913.

PMID:
28226405
7.

Can Assessment of Disease Burden Prior to Changes in Initial COPD Maintenance Treatment Provide Insight into Remaining Unmet Needs? A Retrospective Database Study in UK Primary Care.

Landis SH, Wurst K, Le HV, Bonar K, Punekar YS.

COPD. 2017 Feb;14(1):80-85. doi: 10.1080/15412555.2016.1240159. Epub 2016 Nov 7.

PMID:
27819513
8.

Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.

Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K.

Int J Chron Obstruct Pulmon Dis. 2012;7:183-99. doi: 10.2147/COPD.S29820. Epub 2012 Mar 19.

9.

Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.

Kew KM, Dias S, Cates CJ.

Cochrane Database Syst Rev. 2014 Mar 26;(3):CD010844. doi: 10.1002/14651858.CD010844.pub2. Review.

PMID:
24671923
10.
11.

Emergency Hospital Care for Exacerbation of COPD: Is Inhaled Maintenance Therapy Modified?

Pomares X, Montón C, Baré M, Pont M, Estirado C, Gea J, Quintana JM, Vidal S, Santiago A; IRYSS-COPD Appropriateness study group.

COPD. 2016;13(1):11-8. doi: 10.3109/15412555.2015.1043517. Epub 2015 Sep 29.

12.

First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis.

Price D, Miravitlles M, Pavord I, Thomas M, Wedzicha J, Haughney J, Bichel K, West D.

NPJ Prim Care Respir Med. 2016 Nov 3;26:16061. doi: 10.1038/npjpcrm.2016.61.

13.

The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK.

Edwards SC, Fairbrother SE, Scowcroft A, Chiu G, Ternouth A, Lipworth BJ.

Int J Chron Obstruct Pulmon Dis. 2016 Nov 22;11:2851-2858. eCollection 2016.

14.

The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.

Hanania NA.

Pulm Pharmacol Ther. 2008;21(3):540-50. doi: 10.1016/j.pupt.2007.12.004. Epub 2008 Jan 6. Review.

PMID:
18280761
15.

Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.

Samyshkin Y, Schlunegger M, Haefliger S, Ledderhose S, Radford M.

Int J Chron Obstruct Pulmon Dis. 2013;8:79-87. doi: 10.2147/COPD.S37486. Epub 2013 Jan 30.

16.

Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis.

Oba Y, Chandran AV, Devasahayam JV.

COPD. 2016 Dec;13(6):677-685. Epub 2016 May 5. Review.

PMID:
27148815
17.

Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.

Tan DJ, White CJ, Walters JA, Walters EH.

Cochrane Database Syst Rev. 2016 Nov 10;11:CD011600. Review.

PMID:
27830584
18.

Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohort.

Singh MP.

Int J Chron Obstruct Pulmon Dis. 2013;8:613-9. doi: 10.2147/COPD.S53707. Epub 2013 Dec 9.

19.

The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK.

Brusselle G, Price D, Gruffydd-Jones K, Miravitlles M, Keininger DL, Stewart R, Baldwin M, Jones RC.

Int J Chron Obstruct Pulmon Dis. 2015 Oct 15;10:2207-17. doi: 10.2147/COPD.S91694. eCollection 2015.

20.

Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment Paradigm.

Wilkie M, Finch S, Schembri S.

COPD. 2015;12(5):582-90. doi: 10.3109/15412555.2014.995288. Epub 2015 Mar 16. Review.

Supplemental Content

Support Center